Skip to content

The outcome of a clinical pharmacist-led diabetes education initiative in type II diabetes mellitus patients

The outcome of a clinical pharmacist-led diabetes education initiative in Sudanese patients with type ii diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202311766174946
Enrollment
322
Registered
2023-11-13
Start date
2020-01-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Primary care physicians per usual standard care
education

Sponsors

self sponsored
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Individuals with T2DM aged more than 18 years (adult, older adult) of both sexes and attending the outpatient clinic were eligible for the study.

Exclusion criteria

Exclusion criteria: Any pregnant patients with diabetes, patients currently using medications (like diabetogenic immunosuppressants or antidepressants) that may affect blood glucose levels at the time of the study any patients who were unable to communicate were excluded from the study.

Design outcomes

Primary

MeasureTime frame
changes in Fasting blood glucose, HbA1c levels. Other primary outcome measures included diabetic patients' KAP results, adherence, satisfaction, QoL scores, diabetes-related markers like BMI, LDL, HDL, TC, TG, BP, Scr, and BUN and urine analysis; for the presence of proteinuria.

Secondary

MeasureTime frame
1. Percentage of patients complying with annual lipid testing 2. Percentage of patients compliant with statin therapy 3. Percentage of patients achieving a blood pressure goal of less than 140/90 at the end of the trial period 4. Percentage of patients compliant with annual retinopathy examination 5. Percentage of patients compliant with annual nephropathy examination 6. Percentage of patients who had proteinuria and were taking a kidney-sparing agent (e.g., angiotensin-converting-enzyme inhibitor, angiotensin-receptor blocker, or calcium channel blocker) by study end.

Countries

Sudan

Contacts

Public Contactsafaa badi

assistant professor

safaabadi30@gmail.com+249910616330

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026